The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Roche confirmed its full-year outlook with sales expected to increase in the mid-single-digit percent range at constant exchange rates. The firm added that EPS for full-year 2025 is expected to ...

In today's Pharmalittle roundup, we're reading about Roche and Merck struggles with tariffs, NEJM quizzed by U.S. attorney, ...

By Ludwig Burger (Reuters) -Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff ...

“While there’s still a lot to learn, these findings show that regular intensity exercise, even at low intensity, could go a ...

Several major drugmakers are counting on their manufacturing flexibility to counter potential disruptions from tariffs ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

SWCC hosted its 12th Meals for the Heartland volunteer event, surpassing 750,000 total meals donated from the site throughout ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. | Big Pharma ...

To strengthen its U.S. presence, Roche is building up inventory, ramping up production at three of its U.S. plants and relocating one manufacturing site to the U.S. through a technology transfer, its ...